Biotricity, Inc.

As of February 14, 2020, Biotricity, Inc. is considered a risky investment due to its overvaluation and significant financial distress, reflected in negative valuation metrics and a volatile stock performance, despite a recent year-to-date return of 114.87%.

As of February 14, 2020, Biotricity, Inc. is rated "risky" and overvalued, with concerning financial metrics including a Price to Book Value of -0.44 and a negative P/E ratio, significantly underperforming its peers and the S&P 500.

As of April 8, 2025, Biotricity, Inc. shows a mildly bullish trend driven by daily moving averages, though caution is advised due to mixed signals from weekly indicators and bearish signals from Bollinger Bands.

Biotricity, Inc. is a micro-cap company in the Software Products industry, reporting net sales of $4 million and a net loss of $1 million as of December 2024. It has a market cap of $11.96 million and key metrics indicating a loss-making status with a return on equity of 34.59%.

As of Jun 18, Biotricity, Inc. has a market capitalization of 11.96 million, with net sales of 13.27 million and a net profit of -10.66 million over the last four quarters. The company has shareholder's funds of -29.98 million and total assets of 5.94 million as of Mar 24.